brucella


Brucella Total Antibodies Agglutination Test

Laboratory Fee Schedule

Procedure:  MZZ0135A

CPT: 86622


Brucella Total Antibodies Agglutination Test
Synonym(s): DS Microtiter Procedure for Brucella Agglutination Test
Requisition Form G-2A
Test Description The detection and quantitation of B. abortus IgG and IgM antibodies by the agglutination of safranin-O stained whole cells
Pre-Approval Needed N/A
Supplemental Information Required N/A
Supplemental Form(s) N/A
Performed on Specimens from (sources) Any
Sample/Specimen Type for Testing
  • serum  
Minimum Volume/Size Required 1.0 mL
Storage/Preservation Prior to Shipping
  • Blood should be allowed to clot at room temperature then centrifuged.
  • Serum can be used if particulates are removed via filtration or by using lipid clearing reagents and centrifugation.
  • Serum can be stored at  2°C  to 8°C  if tested within two days or should be Frozen at ≤ -15°C or colder if not tested within 2 days
Transport Medium N/A
Specimen Labeling
  • Two patient-specific identifiers required (e.g. patient full name, date of birth, Medical Record number)
  • Identifiers on specimen must exactly match submission form.
Shipping and Specimen Handling Requirements
  • Ship according to Dangerous Goods Regulations, IATA, and/or CFR 49.
  • Handle as infectious agent using universal precautions. 
  • Triple contain in accordance with federal shipping regulations for infectious agents.
    Additional forms & resources
Method Antibody agglutination test
Turn-around Time 3 working days
Interferences/Limitations Hemolytic, hyperlipemic and bacterial contamination can produce erroneous results in serologic tests.
Common Causes for Rejection
  • Insufficient quantity
  • unacceptable specimen type or source
  • improper shipping conditions
  • expired media or collection container
  • discrepancies between specimen label and submission form
  • incomplete or missing submission form.
Additional Information This test can provide presumptive evidence of Brucellosis.  Results should be considered in combination with other clinical, laboratory and epidemiologic findings.

Last updated December 13, 2021